These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 17521711)

  • 21. Changes in platelet count as a predictive tool in sickle cell acute vaso-occlusive crises: a pediatric study.
    Shanley LA; Ebeling M; Titus MO
    Clin Pediatr (Phila); 2011 Jul; 50(7):657-61. PubMed ID: 21382920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythropoiesis and serum sVCAM-1 levels in adults with sickle cell disease.
    Duits AJ; Rojer RA; van Endt T; MacGillavry MR; ten Cate H; Brandjes DP; Schnog JB
    Ann Hematol; 2003 Mar; 82(3):171-4. PubMed ID: 12634950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombopoietin or interleukin-6 has no effect on thrombocytopenia of cirrhosis.
    Ozer B; Serin E; Sezgin N; Cosar A; Güclü M; Gur G; Yilmaz U; Boyacioglu S
    Hepatogastroenterology; 2007 Jun; 54(76):1187-91. PubMed ID: 17629067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Childhood sickle cell crises: clinical severity, inflammatory markers and the role of interleukin-8.
    Etienne-Julan M; Belloy MS; Decastel M; Dougaparsad S; Ravion S; Hardy-Dessources MD
    Haematologica; 2004 Jul; 89(7):863-4. PubMed ID: 15257940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is interleukin 6 the physiological regulator of thrombopoiesis?
    Straneva JE; van Besien KW; Derigs G; Hoffman R
    Exp Hematol; 1992 Jan; 20(1):47-50. PubMed ID: 1577093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.
    Lanaro C; Franco-Penteado CF; Albuqueque DM; Saad ST; Conran N; Costa FF
    J Leukoc Biol; 2009 Feb; 85(2):235-42. PubMed ID: 19004988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary function studies in Kuwaiti children with sickle cell disease and elevated Hb F.
    Hijazi Z; Onadeko BO; Khadadah M; Haider MZ; Adekile AD; Al-Habashi H
    Int J Clin Pract; 2005 Feb; 59(2):163-7. PubMed ID: 15854191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura.
    Kajihara M; Okazaki Y; Kato S; Ishii H; Kawakami Y; Ikeda Y; Kuwana M
    J Gastroenterol Hepatol; 2007 Jan; 22(1):112-8. PubMed ID: 17201890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-annexin V IgG and IgM antibodies in sickle cell disease patients with vaso-occlusive crisis.
    Sater MS; Mahdi N; Al-Absi IK; Al-Subaie AM; Al-Ola K; Mohammed FA; Almawi WY
    Ann Hematol; 2011 Sep; 90(9):1031-6. PubMed ID: 21340721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders.
    Ceresa IF; Noris P; Ambaglio C; Pecci A; Balduini CL
    Platelets; 2007 Dec; 18(8):579-82. PubMed ID: 18041648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet P-selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis.
    Garbaraviciene J; Diehl S; Varwig D; Bylaite M; Ackermann H; Ludwig RJ; Boehncke WH
    Exp Dermatol; 2010 Aug; 19(8):736-41. PubMed ID: 20482619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel.
    Ohno K; Tanaka H; Samata N; Jakubowski JA; Tomizawa A; Mizuno M; Sugidachi A
    Thromb Res; 2014 Oct; 134(4):889-94. PubMed ID: 25130912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of tumor stage and nephrectomy on CD62P expression and sP-selectin concentration in renal cancer.
    Mantur M; Kemona H; Kozłowski R; Kemona-Chetnik I
    Neoplasma; 2003; 50(4):262-5. PubMed ID: 12937838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet aggregation and physiological anticoagulants in sickle-cell disease.
    Bashawri LA; Al-Mulhim AA; Ahmed MA; Bahnassi AA
    East Mediterr Health J; 2007; 13(2):266-72. PubMed ID: 17684847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of low-dose warfarin on D-dimer levels during sickle cell vaso-occlusive crisis: a brief report.
    Ahmed S; Siddiqui AK; Iqbal U; Sison CP; Shahid RK; Sheth M; Patel DV; Russo LA
    Eur J Haematol; 2004 Mar; 72(3):213-6. PubMed ID: 14962240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet count and platelet factor 3 (PF-3) availability in sickle cell disease.
    Famodu AA; Oduwa D
    Br J Biomed Sci; 1995 Dec; 52(4):323-4. PubMed ID: 8555788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significance of platelet activation in sickle cell anaemia.
    Ibanga IA
    Niger J Med; 2006; 15(2):148-50. PubMed ID: 16805172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inflammatory potential of neutrophils detected in sickle cell disease.
    Lum AF; Wun T; Staunton D; Simon SI
    Am J Hematol; 2004 Jun; 76(2):126-33. PubMed ID: 15164377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood mononuclear cells and platelets have abnormal fatty acid composition in homozygous sickle cell disease.
    Ren H; Okpala I; Ghebremeskel K; Ugochukwu CC; Ibegbulam O; Crawford M
    Ann Hematol; 2005 Sep; 84(9):578-83. PubMed ID: 15809883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic thrombocytopenia of childhood: use of non-invasive methods in clinical evaluation.
    Rajantie J; Javela K; Joutsi-Korhonen L; Kekomäki R
    Eur J Haematol; 2004 Apr; 72(4):268-72. PubMed ID: 15089765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.